Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions

Part of paid clinical trials in Houston, Texas.

Sponsor
The University of Texas Health Science Center, Houston
Study ID
NCT07737171
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) — DEVICE
    EUS-guided Radiofrequency Ablation (RFA) consists of the application of alternating current with a frequency of 350-500 kHz (coincidentally the frequency range of radio broadcasts as well) to the target tissue via a special electrode located at the tip of the endoscope.

Study Details

This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.

Key Dates

First listed
Jul 30, 2026
Start date
Apr 7, 2026
Status verified
Jul 2026
Primary completion
Apr 1, 2033
Completion
Apr 1, 2033

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Adult patients who undergo EUS-RFA for treatment of pancreatic lesions

Primary Outcome Measure

Number of participants for whom there is technical success of tumor treatment [ Time Frame: From time of the procedure to about 3 months post procedure ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas Health Science Center at HoustonHoustonTexas77030
Amatullah Alibhai, MBA
[email protected]
713-500-6658
Nicole Fatheree, BBA
[email protected]
713-500-5669

Find similar trials in Houston, TX

Nationwide
Pancreatic cancer trialsOncology trialsGI oncology trials
By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
The University of Texas Health Science Center at Houston· Houston, TX

Related Studies